WALTHAM, Mass., Aug. 23 /PRNewswire-FirstCall/ -- Thermo Electron Corporation , a premier supplier of analytical solutions, announced today a new agreement with the Novartis Institutes for BioMedical Research, Inc. (NIBRI) in Cambridge, Mass. Under this agreement, Thermo will supply Ultra High Throughput Screening (uHTS) automation technologies to Novartis' new global research headquarters in Cambridge.
After a competitive review and selection process, NIBRI chose Thermo's CRS Dimension4(TM) Distributed Motion System for high throughput screening to enhance its research and drug discovery efforts. Dimension4 is a modular laboratory automation platform that provides reliable, flexible, and scalable automation of virtually any laboratory assay, method, or protocol.
"As Novartis enters a new chapter with the opening of its global research headquarters here in Massachusetts, Thermo will work closely with NIBRI to facilitate and augment the drug discovery process with what we feel are the best automation tools available," said Marc Casper, president, Thermo Electron Life and Laboratory Sciences. "We will act as NIBRI's support system by providing a breadth of quality HTS and automation products, services and support."
About Thermo Electron
Thermo Electron Corporation is the world leader in analytical instruments. Our instrument solutions enable our customers to make the world a healthier, cleaner and safer place. Thermo's Life and Laboratory Sciences business provides analytical instruments, scientific equipment, services, and software solutions for life science, drug discovery, clinical, environmental, and industrial laboratories. Thermo's Measurement and Control business is dedicated to providing analytical instruments used in a variety of manufacturing processes and in-the-field applications including those associated with safety and homeland security. Based near Boston, Massachusetts, Thermo has revenues of more than $2 billion, and employs approximately 10,000 people in 30 countries. For more information, visit http://www.thermo.com/.
The following constitutes a "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward- looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth under the heading "Forward-Looking Statements" in the company's Quarterly Report on Form 10-Q for the fiscal quarter ended July 3, 2004. These include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change, dependence on customers that operate in cyclical industries, general worldwide economic conditions and related uncertainties, the effect of changes in governmental regulations, dependence on customers' capital spending policies and government funding policies, use and protection of intellectual property, exposure to product liability claims in excess of insurance coverage, retention of contingent liabilities from businesses we sold, realization of potential future savings from new productivity initiatives, implementation of new branding strategy, implementation of strategies for improving internal growth, the effect of exchange rate fluctuations on international operations, identification, completion and integration of new acquisitions and potential impairment of goodwill from previous acquisitions. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Media Contact Information: Investor Contact Information:
Lori Gorski J. Timothy Corcoran
Phone: 781-622-1242 Phone: 781-622-1111
E-mail: email@example.com E-mail: firstname.lastname@example.org
Thermo Electron Corporation